The Safety and Efficacy of Rituximab-Based Regimen in Atypical Membranous Nephropathy: A Single Center Retrospective Cohort Study

References

• Austin HA 3rd, Antonovych TT, MacKay K, Boumpas DT, Balow JE. Membranous nephropathy. Ann Intern Med. 1992;116(8):672–682. doi:10.7326/0003-4819-116-8-672
   PubMed Web of Science ®Google Scholar
• Glassock RJ. Secondary membranous glomerulonephritis. Nephrol Dial Transplant. 1992;7(Suppl 1):64–71.
   PubMed Web of Science ®Google Scholar
• Moroni G, Ponticelli C. Secondary membranous nephropathy. A narrative review. Front Med. 2020;7:611317. doi:10.3389/fmed.2020.611317
   Web of Science ®Google Scholar
• Wang WX, Hu CY. Value of immunofluorescence-mediated detection of Ig, C1q, C3, and FRA for the identification and diagnosis of atypical membranous nephropathy. Eur Rev Med Pharmacol Sci. 2017;21(23):5415–5419. doi:10.26355/eurrev_201712_13929
   PubMed Web of Science ®Google Scholar
• Jiang Z, Cai M, Dong B, et al. Clinicopathological features of atypical membranous nephropathy with unknown etiology in adult Chinese patients. Medicine. 2018;97(32):e11608. doi:10.1097/MD.0000000000011608
   PubMed Web of Science ®Google Scholar
• Jiang Z, Cai M, Dong B, et al. Renal outcomes of idiopathic and atypical membranous nephropathy in adult Chinese patients: a single center retrospective cohort study. BMC Nephrol. 2021;22(1):148. doi:10.1186/s12882-021-02348-4
   PubMed Web of Science ®Google Scholar
• van den Brand JA, van Dijk PR, Hofstra JM, Wetzels JF. Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. J Am Soc Nephrol. 2014;25(1):150–158. doi:10.1681/ASN.2013020185
   PubMed Web of Science ®Google Scholar
• Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007;18(6):1899–1904. doi:10.1681/ASN.2007020166
   PubMed Web of Science ®Google Scholar
• Dahan K, Debiec H, Plaisier E, et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol. 2017;28(1):348–358. doi:10.1681/ASN.2016040449
   PubMed Web of Science ®Google Scholar
• Fernandez-Juarez G, Rojas-Rivera J, Logt AV, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021;99(4):986–998. doi:10.1016/j.kint.2020.10.014
   PubMed Web of Science ®Google Scholar
• Fervenza FC, Canetta PA, Barbour SJ, et al. A multicenter randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy (MENTOR). Nephron. 2015;130(3):159–168. doi:10.1159/000430849
   PubMed Web of Science ®Google Scholar
• Lu W, Gong S, Li J, Luo H, Wang Y. Efficacy and safety of rituximab in the treatment of membranous nephropathy: a systematic review and meta-analysis. Medicine. 2020;99(16):e19804. doi:10.1097/MD.0000000000019804
   PubMed Web of Science ®Google Scholar
• Scolari F, Dallera N, Gesualdo L, et al. Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial. BMJ Open. 2019;9(12):e029232. doi:10.1136/bmjopen-2019-029232
   PubMed Web of Science ®Google Scholar
• Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4):S1–S276.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. doi:10.7326/0003-4819-150-9-200905050-00006
   PubMed Web of Science ®Google Scholar
• Rojas-Rivera JE, Carriazo S, Ortiz A. Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal. Clin Kidney J. 2019;12(5):629–638. doi:10.1093/ckj/sfz127
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Patrizia P, Del VL, Locatelli F. The evolution of the therapeutic approach to membranous nephropathy. Nephrol Dial Transplant. 2020;36(5):768–773.
   Web of Science ®Google Scholar
• Nikolopoulou A, Griffith M. MENTOR heralds a new era of therapy for membranous nephropathy. Nat Rev Nephrol. 2019;15(11):664–666. doi:10.1038/s41581-019-0200-1
   PubMed Web of Science ®Google Scholar
• Fiorentino M, Tondolo F, Bruno F, et al. Treatment with rituximab in idiopathic membranous nephropathy. Clin Kidney J. 2016;9(6):788–793. doi:10.1093/ckj/sfw091
   PubMed Web of Science ®Google Scholar
• van den Brand J, Ruggenenti P, Chianca A, et al. Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy. J Am Soc Nephrol. 2017;28(9):2729–2737. doi:10.1681/ASN.2016091022
   PubMed Web of Science ®Google Scholar
• Scolari F, Delbarba E, Santoro D, et al. Rituximab or Cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO Randomized Trial. J Am Soc Nephrol. 2021;32:972–982. doi:10.1681/ASN.2020071091
   PubMed Web of Science ®Google Scholar
• Sam R, Joshi A, James S, et al. Lupus-like membranous nephropathy: is it lupus or not? Clin Exp Nephrol. 2015;19(3):395–402. doi:10.1007/s10157-014-1002-1
   PubMed Web of Science ®Google Scholar
• Xu J, Shen C, Lin W, et al. Single-cell profiling reveals transcriptional signatures and cell-cell crosstalk in Anti-PLA2R positive idiopathic membranous nephropathy patients. Front Immunol. 2021;12:683330. doi:10.3389/fimmu.2021.683330
   PubMed Web of Science ®Google Scholar
• Cravedi P. Complement in membranous nephropathy: what we thought we knew and what we really know. Kidney Int. 2021;100(3):499–501. doi:10.1016/j.kint.2021.03.010
   PubMed Web of Science ®Google Scholar
• Reinhard L, Stahl RAK, Hoxha E. Is primary membranous nephropathy a complement mediated disease? Mol Immunol. 2020;128:195–204. doi:10.1016/j.molimm.2020.10.017
   PubMed Web of Science ®Google Scholar
• Ma H, Sandor DG, Beck LH Jr. The role of complement in membranous nephropathy. Semin Nephrol. 2013;33(6):531–542. doi:10.1016/j.semnephrol.2013.08.004
   PubMed Web of Science ®Google Scholar
• Segawa Y, Hisano S, Matsushita M, et al. IgG subclasses and complement pathway in segmental and global membranous nephropathy. Pediatr Nephrol. 2010;25(6):1091–1099. doi:10.1007/s00467-009-1439-8
   PubMed Web of Science ®Google Scholar
• Jennette JC, Hipp CG. Immunohistopathologic evaluation of C1q in 800 renal biopsy specimens. Am J Clin Pathol. 1985;83(4):415–420. doi:10.1093/ajcp/83.4.415
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Chiurchiu C, Brusegan V, et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol. 2003;14(7):1851–1857. doi:10.1097/01.ASN.0000071511.35221.B3
   PubMed Web of Science ®Google Scholar
• Pourcine F, Dahan K, Mihout F, et al. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: a single-centre study over 14 years. PLoS One. 2017;12(3):e0173201. doi:10.1371/journal.pone.0173201
   PubMed Web of Science ®Google Scholar
• Qin HZ, Zhang MC, Le WB, et al. Combined assessment of phospholipase A2 receptor autoantibodies and glomerular deposits in membranous nephropathy. J Am Soc Nephrol. 2016;27(10):3195–3203. doi:10.1681/ASN.2015080953
   PubMed Web of Science ®Google Scholar
• Huang L, Dong QR, Zhao YJ, Hu GC. Rituximab for the management of idiopathic membranous nephropathy: a meta-analysis. Int Urol Nephrol. 2021;53(1):111–119. doi:10.1007/s11255-020-02633-5
   PubMed Web of Science ®Google Scholar
• Hofstra JM, Debiec H, Short CD, et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23(10):1735–1743. doi:10.1681/ASN.2012030242
   PubMed Web of Science ®Google Scholar
• Hoxha E, Thiele I, Zahner G, Panzer U, Harendza S, Stahl RA. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol. 2014;25(6):1357–1366. doi:10.1681/ASN.2013040430
   PubMed Web of Science ®Google Scholar
• Hoxha E, Harendza S, Pinnschmidt H, Panzer U, Stahl RA. PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system. PLoS One. 2014;9(10):e110681. doi:10.1371/journal.pone.0110681
   PubMed Web of Science ®Google Scholar
• Kanigicherla D, Gummadova J, McKenzie EA, et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int. 2013;83(5):940–948.
   PubMed Web of Science ®Google Scholar
• Hoxha E, Harendza S, Pinnschmidt H, Panzer U, Stahl RA. M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clin J Am Soc Nephrol. 2014;9(11):1883–1890. doi:10.2215/CJN.03850414
   PubMed Web of Science ®Google Scholar
• Hofstra JM, Beck LH Jr., Beck DM, Wetzels JF, Salant DJ. Anti-phospholipase A(2) receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2011;6(6):1286–1291. doi:10.2215/CJN.07210810
   PubMed Web of Science ®Google Scholar
• Beck LH Jr., Fervenza FC, Beck DM, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol. 2011;22(8):1543–1550.
   PubMed Web of Science ®Google Scholar
• Bech AP, Hofstra JM, Brenchley PE, Wetzels JF. Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014;9(8):1386–1392.
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-phospholipase A2 Receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol. 2015;26(10):2545–2558. doi:10.1681/ASN.2014070640
   PubMed Web of Science ®Google Scholar
• Gao S, Cui Z, Wang X, et al. Rituximab therapy for primary membranous nephropathy in a Chinese cohort. Front Med. 2021;8:663680. doi:10.3389/fmed.2021.663680
   Web of Science ®Google Scholar
• Cravedi P, Sghirlanzoni MC, Marasa M, Salerno A, Remuzzi G, Ruggenenti P. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. Am J Nephrol. 2011;33(5):461–468. doi:10.1159/000327611
   PubMed Web of Science ®Google Scholar
• Zonozi R, Laliberte K, Huizenga NR, et al. Combination of rituximab, low-dose cyclophosphamide, and prednisone for primary membranous nephropathy: a case series with extended follow Up. Am J Kidney Dis. 2021;78(6):793–803. doi:10.1053/j.ajkd.2021.04.014
   PubMed Web of Science ®Google Scholar